|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Head and Neck Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Head and Neck Neoplasms | |||||
| Salivary Gland Diseases | |||||
| Salivary Gland Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Mouth Diseases | |||||
| Mouth Neoplasms | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Stomatognathic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| trastuzumab | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Dana-Farber Cancer Institute | |||||
| National Cancer Institute (NCI) | |||||